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Abstract
Background: Immune activation that results due to the aberrant proliferation of lymphocytes
leads to inflammation and graft rejection in organ transplant recipients. We hypothesize that the
cell cycle control and inflammation are parallel events, inhibition of cellular proliferation by cyclin
kinase inhibitor specifically p21 will limit inflammation and prevent allograft rejection.
Methods: We performed in vitro and in vivo studies using lymphocytes, and rat heart transplant
model to understand the role of cyclins and p21 on mitogen and allo-induced lymphocyte activation
and inflammation. Lymphocyte proliferation was studied by 3H-thymidine uptake assay and mRNA
expression was studied RT-PCR.
Results: Activation of allo- and mitogen stimulated lymphocytes resulted in increased expression
of cyclins, IL-2 and pro-inflammatory cytokines, which was inhibited by cyclosporine. The over-
expression of p21 prolonged graft survival in a completely mismatched rat heart transplant model
resulted by inhibiting circulating and intra-graft expression of proinflammatory cytokines.
Conclusion: Cyclins play a significant role in transplant-induced immune activation and p21 over-
expression has potential to inhibit T cell activation and inflammation. The results from this study
will permit the design of alternate strategies by controlling cell cycle progression to achieve
immunosuppression in transplantation.
Background
Alloimmune activation, caused by aberrant T lymphocyte
proliferation is one of the key post transplant events in
organ transplant recipients. Current immunosuppressive
drugs are therefore designed to inhibit T lymphocyte pro-
liferation. Our previous studies have demonstrated that
immunosuppressive drugs, cyclosporine (CsA) tacrolimus
(TAC), and sirolimus (SRL) besides inhibiting lym-
phocyte proliferation and IL-2 also induce the expression
of TGF-β and other fibrogenic molecules [1-3] leading to
nephrotoxicity and chronic rejection. Therefore, there is a
need to develop alternate strategies to achieve immuno-
suppression for increased graft survival with least nephro-
toxicity. The most effective immunosuppression can be
achieved by the direct inhibition of T lymphocyte prolif-
eration. Since the expression of cyclins and cyclin-depend-
ent kinases and pro-inflammatory cytokines is increased
during T lymphocyte proliferation (4), control of T cell
proliferation by regulating the expression of cyclins would
potentially inhibit allo-immune activation and inflamma-
tion. p21WAF1/CIP1 is one of the most potent cyclin
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kinase inhibitor and therefore has potential to control the
expression of cyclins and T cell activation.
We have demonstrated that CsA, TAC and SRL [4-6]
induces the expression of cyclin kinase inhibitor
p21WAF1/CIP1 and also in vitro and in vivo over-expres-
sion of p21WAF1/CIP1 in lymphocytes results in
decreased response to mitogenic stimuli and greater sensi-
tive to the inhibitory effects of cyclosporine [7]. The
present study was designed to study the expression of cyc-
lins during T cell activation, allograft rejection, and the
effect of p21WAF1/CIP1 on mitogenic and allogeneic
stimulation, pro-inflammatory cytokines and graft sur-
vival in a rat heart transplant model.
Methods
Preparation of lymphocytes and experimental protocol
Lymphocytes from the normal individuals (n = 4,
obtained from Blood Center of Greater Milwaukee, Mil-
waukee) were separated as described [1]. For mRNA stud-
ies, lymphocytes (1 × 106/ml) were cultured with PHA (2
µg/ml), with and without CsA (100 mg/ml) for 4 h, cells
were washed twice with PBS and the cells were stored in
Trizol at -80 C for RNA preparation.
Rat cardiac transplantation
Hetrotopic heart transplants were performed as described
by us [8]. We used Lewis (LEW, RT11) and Wistar-Furth
(WF RT1u) rats, which represent complete genetic dispar-
ity at both major and minor histocompatibility loci. Iso-
grafts were performed in LEW-LEW while allogeneic
transplantations were performed in WF-LEW transplant
combinations. Immunosuppression was accomplished
using CsA at a dosage of 2.5 mg/kg for the whole duration
of the experiment described. Rats were monitored daily
for evidence of allograft slowing and failure and at the
time of rejection, animal s were sacrificed and spleens
were used to prepare lymphocytes and organs were snap
frozen in liquid nitrogen and stored at -80 C till isolation
of RNA.
Detection of mRNA by reverse transcription and 
polymerase chain reaction (PCR) in allografts and 
lymphocytes
Total RNA was isolated from lymphocytes with Trizol
(Invitrogen, Carlsbad, CA) and tissues with SV RNA isola-
tion kit (Promega, Madison, WI). Purity of RNA was con-
firmed by a ratio of 260/280 nm. 1 µg of RNA was reverse
transcribed into cDNA using a superscript reverse tran-
scription kit from Invitrogen (Carlsbad CA). The amplifi-
cation of specific mRNA expression was achieved by
polymerase chain reaction (PCR) using specific primer
sequences for p21WAF1/CIP1, β-actin, IL-2, TNF-α; Cyc-
lin G, Cyclin E, Cyclin D3, IL-6, and IL-10 are described by
us [4-6]. The PCR products were resolved in 1% agarose
gel electrophoresis, ethidium bromide stained specific
bands were visualized under UV light and photographed.
The densitometric analysis of specific bands was made
using Alpha-Imager (Alpha Innotech Corp, San Leandro,
CA) and data are represented as the ratio of the specific
gene to β-actin. We performed cycle analysis for each
primer pair to select a cycle number for amplification for
each gene studied.
Jurkat T cells proliferation assay
Cell proliferation was determined using 3H-thymidine
incorporation as previously described (1–2). All assays
were performed in triplicate. A total of 3 individual exper-
iments investigating the proliferation of unaltered and
p21WAF1/CIP1 Jurkat cells [described in ref. 7] were per-
formed in unstimulated and activated with PHA. Briefly,
200,000 cells were added to each well of a round bottom
96-well plate. PHA (2 µg/ml) was added to the wells, con-
trols were without PHA. The cells were cultured for 64 h at
37°C in 95% air and 5% CO2 enriched environment. The
cultures were pulsed with 3H Thymidine (1 µCi/well) for
the last 16 h of incubation, cells were harvested and radi-
oactivity counted using a scintillation counter. 3H -Thymi-
dine uptake was expressed as the mean counts per minute
of triplicate samples. The magnitude of Jurkat T cells pro-
liferation from unaltered and p21WAF1/CIP1-augmented
cells were investigated at rest following mitogen
stimulation.
In vivo transfection of p21WAF1/CIP1
p21 sense plasmid DNA
Plasmid DNA was isolated from competent E-coli cells
transformed with either the empty pcDNA3.1/Zeo vector
(Invitrogen, Carlsbad CA) or the vector containing the
full-length p21WAF1/CIP1 gene in the sense direction
described by us [7].
Mixed Lymphocyte Reaction (MLR)
MLR was performed with splenocytes from isografts,
untreated and CsA treated transplant recipients (LEW) as
responders and irradiated splenocytes from donor strain
(WF) as stimulators. The stimulator or responder cells
were cultured alone as negative controls. 3H Thymidine
uptake was expressed as the median counts per minute of
triplicate samples. The extent of proliferation determined
the allo-reactivity of among these groups of mice and rats.
Data analysis
Differences between groups were determined using two-
tailed unpaired T test with significance considered present
at a p value of less than 0.05. Statistical analysis was per-
formed using a software program from GraphPad Soft-
ware, Inc., San Diego, CA 92121 USA. The results are
expressed as M ± SEM.BMC Immunology 2005, 6:22 http://www.biomedcentral.com/1471-2172/6/22
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Results
Effect of inhibition of lymphocyte proliferation on IL-2, 
cyclins, TNF-α, IL-6 and p21WAF1/CIP1 mRNA
To understand the relationship between cyclins, pro-
inflammatory cytokines and p21WAF1/CIP1 during lym-
phocyte proliferation and inhibition, we studied the
mRNA expression of cyclin G, cyclin D3, IL-2, IL-6, TNF-
α, and p21WAF1/CIP1 in lymphocytes activated in the
presence or absence of CsA. The expression of IL-2 mRNA
was used as a control for activation and inhibition of lym-
phocytes. The results from a representative of three con-
secutive experiments are shown in Figure 1A. Mitogen
activation of lymphocytes resulted in an increase in IL-2,
cyclins G and D3, TNF-α, IL-6 and p21WAF1/CIP1 mRNA
(lanes 2), when compared to untreated lymphocytes (lane
1). As expected, CsA inhibited the expression of IL-2, and
TNF-α mRNA however IL-6 mRNA was not completely
inhibited. More interestingly, whereas the inhibition of
lymphocytes by CsA also resulted in a significantly
decreased expression of cyclins G, and D3 mRNA, and an
increased expression of cyclin kinase inhibitor p21WAF1/
CIP1 mRNA (lane 3) was observed.
The results obtained from three consecutive experiments
as the ratio of each gene with β-actin (Mean ± SEM) are
presented in Figure 1B. A statistically significant decrease
in pro-inflammatory cytokines IL-2 (p < 0.016), IL-6 (p <
0.02), TNF-α (p < 0.03) and cyclins; Cyclin D3 (p < 0.01)
and Cyclin G (p < 0.008) was observed in sharp contrast
to a significant increase in p21 (p < 0.03) in lymphocytes
activated in the presence of CsA. CsA treatment also
resulted in increased expression of p21 protein in acti-
vated lymphocytes (Figure 1C). This increase was about 2
fold.
Expression of cyclins in lymphocytes from rejecting and 
non-rejecting rats
The rationale for these experiments is our hypothesis that
in untreated and rejecting recipients of cardiac trans-
plants, alloimmune activation will result in an increased
expression of mRNA for cyclins in lymphocytes and the
treatment with CsA will inhibit alloimmune activation
and hence mRNA expression of cyclins leading to the pro-
longation of graft survival. To test this, we studied the
mRNA expression of cyclins G, D3 and E in lymphocytes
from rejecting (untreated) and non-rejecting recipients
(CsA treated) in a heterotopic rat cardiac allograft model
using a fully MHC mismatched [WF (RTlu) into LEW
(RTll)] strain combination. The results (Figure 2A) dem-
onstrate that the expression of cyclins G, D3 and E was sig-
nificantly higher in lymphocytes obtained from untreated
recipients of cardiac allografts (lanes 4, 5) compared to
those treated with CsA (2.5 mg/kg) for 30 days (lanes 1–
3). The untreated rats rejected graft between 8–10 days
after transplant whereas CsA treated rats did not reject and
were sacrificed on day 30th. Almost identical expression of
the housekeeping gene β-actin in the lymphocytes of these
rats is also shown (Figure 2A). The results from the
untreated and CsA treated recipients are also presented as
the ratio of each cyclin to β-actin (Mean ± SEM); cyclin D3
(0.43 ± 0.05 vs 0.16 ± 0.04, p < 0.03); cyclin G (0.45 ±
CsA inhibits cyclins, IL-6 and TNF-α and induces p21WAF1/ CIP1 mRNA expression in activated lymphocytes Figure 1
CsA inhibits cyclins, IL-6 and TNF-α and induces 
p21WAF1/CIP1 mRNA expression in activated lym-
phocytes. A). A picture representative of three different 
experiments demonstrating cyclins (D3 and G), p21WAF1/
CIP1, IL-6, TNF-α and induction of mRNA expression in acti-
vated lymphocytes (lane 2) with CsA (lanes 3). The lower 
bands in IL-2 mRNA area are primer dimers. B) Mean ± SEM 
(n = 3) of the ratio of cyclins, IL-6 and TNF-α and induces 
p21WAF1/CIP1 with β-actin is shown for lymphocytes either 
unctivated or activated with and without CsA. The p values 
signify the statistical significance for mRNA expression in 
lymphocytes activated with and with out CsA for each gene. 
C) Western blot analysis for p21 protein in lymphocytes unc-
tivated (lane 1), activated (lane 2) with CsA (lane 3).
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0.02 vs 0.1 ± 0.03, p < 0.003) and cyclin E (0.46 ± 0.03 vs
0.1 ± 0.04, p < 0.007). These results (Figure 2B) obtained
from a semi-quantitative PCR analysis demonstrate that
the aberrant alloimmune activation responsible for graft
rejection is associated with the increased expression of
cyclins. More significantly, CsA treatment significantly
decreased mRNA expression of cyclins, alloimmune acti-
vation and prolongation of graft survival.
Correlation of the expression of cyclins and pro-
inflammatory cytokines in allo-immune
To confirm that the increased expression of cyclins in lym-
phocytes from rejecting rats was due to alloimmune acti-
vation, we performed mixed lymphocyte reaction (MLR)
using spleen cells from donor animals (WF) as stimulators
and splenocytes from recipients (LEW) as responders.
Three groups were studied; isografts (control), untreated
allografts (A), and CsA-treated allografts (B). After five-
day MLR lymphocytes were harvested and washed. RNA
was prepared; reverse transcribed to cDNA, and was
amplified by RT-PCR for cyclin D3, IFN-γ, TNF-α, IL-6 and
IL-10 mRNA. As shown in the Figure 2C the mRNA
expression of cyclin D3 was higher in lymphocytes from
untreated allografts group A as compared to lymphocytes
from isografts group B. This increased expression of cyclin
D3 correlated with the pro-inflammatory cytokines IFN-γ
and TNF-α mRNA expression. The expression of IL-6 and
IL-10 mRNA was not statistically significant between
groups A and B. CsA treatment decreased cyclin D3
expression by 50% and inhibited statistically significant
(p < 0.03) IFN-γ mRNA expression. Lymphocyte activa-
tion in MLR assay was quantified by 3H-thymidine uptake
assay. Proliferation of lymphocytes from untreated allo-
grafts was significantly higher (two tailed p value = 0.02)
compared to CsA- treated allografts (Mean ± SEM of
counts per minute, n = 3, 11796 ± 728 vs 7575 ± 360).
These results support our conclusions from rat transplant
studies that the alloimmune results in increased expres-
sion of cyclins mRNA that correlates with production of
pro-inflammatory cytokines. Allo-immune activation is
demonstrated by increased lymphocyte proliferation from
MLR assay, which decreased in CsA treated animals.
p21WAF1/CIP1 over-expression, lymphocyte proliferation 
and IL-2 expression
To confirm our previous in vitro and in vivo studies that
p21WAF1/CIP1 over-expression will inhibit lymphocyte
proliferation and IL-2 expression, we conducted studies
using Jurkat T cells. Jurkat T cells were transfected with
empty vector plasmid DNA (control DNA) and
p21WAF1/CIP1 sense plasmid DNA. We used Jurkat T
cells for these experiments because of the ease with which
these cells can be transfected as compared to primary T
cells; these p21WAF1/CIP1 over-expressing Jurkat T cells
are described previously [7]. No differences were observed
in the proliferation of normal Jurkat cells and Jurkat cells
transfected with empty vector DNA. Control and
p21WAF1/CIP1 over-expressing Jurkat T cells were acti-
vated with PHA (2 µg/ml) for 4 h for IL-2 mRNA expres-
sion studies and 24 h for proliferation studies using 3[H]-
In vitro and in vivo mRNA expression of Cyclins relates to  alloimmune activation Figure 2
In vitro and in vivo mRNA expression of Cyclins 
relates to alloimmune activation: A: Cyclins; D3, E and 
G and β-actin mRNA expression in lymphocytes isolated 
from spleens of rat heart transplant recipients. Untreated 
(lanes 4,5), CsA treated (lanes 1,2,3). B: Mean ± SEM of the 
ratio cyclins with β-actin, p values are calculated between 
densitometric numbers of untreated and CsA treated trans-
plant recipient. C: Cyclin D3 and pro-inflammatory cytokines 
mRNA expression in lymphocyte from MLR assay using stim-
ulants from donor strain with responders from donor strain 
(Control) untreated rejecting transplant recipients (A) and 
CsA treated non rejecting transplant recipients (B). The p 
values represent the statistical significance between ratio of 
densitometric numbers for each gene with β-actin from 
untreated (Group A) vs CsA (Group B) treated transplant 
recipients.
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thymidine uptake assay. The results demonstrate that the
control Jurkat cells, but not p21WAF1/CIP1 over-express-
ing Jurkat T cells, responded to mitogenic stimulation by
PHA (Figure 3A). PHA stimulation resulted in an
increased expression of IL-2 mRNA in Jurkat cells, not in
p21WAF1/CIP1 over-expressing Jurkat cells (Figure 3B).
These results indicated that the p21WAF1/CIP1 over-
expression rendered Jurkat cells unresponsive to
mitogenic stimuli, possibly p21WAF1/CIP1 over-expres-
sion did not allow increased cyclin expression, thereby
preventing lymphocyte activation by PHA. An increased
expression of p21 protein in four different sets of p21-
overexpressing Jurkat T cells (lanes 2–4) compared to Jur-
kat T cells transfected with empty vector plasmid DNA
(lane 1) is also shown (Figure 3C) suggesting the
increased p21 protein expression in these p21 overex-
pressing cells.
Effect of p21WAF1/CIP1 over-expression on graft survival 
in a rat heart transplant model
p21WAF1/CIP1 over-expression in Rats
Encouraged by our studies with mice, which demon-
strated that transfection with p21WAF1/CIP1 sense plas-
mid DNA resulted in decreased lymphocyte proliferation,
we performed pilot experiments to determine if in vivo
over expression of p21 will also result in improved graft
survival in a rat cardiac transplant model. We injected
(intramuscularly) either p21WAF1/CIP1 sense plasmid
DNA or empty vector plasmid DNA (1 mg) to 4 rats in
each group. Since in our experiments with mice we used
100 µg of DNA, based on difference in the average weights
of a rat and mouse, we used 10 times more DNA in rats.
Seven days after the injection, animals were sacrificed,
RNA was prepared from heart (h), liver (l), kidney (k) and
spleen (s), reverse transcribed to cDNA and amplified for
p21WAF1/CIP1 mRNA. Results shown in Figure 4A dem-
onstrate that injection with p21WAF1/CIP1 sense plasmid
DNA but not with empty vector plasmid DNA resulted in
an over-expression of p21WAF1/CIP1 mRNA. These
results also demonstrate that p21WAF1/CIP1 transgenesis
using intramuscular injection of plasmid DNA can be
achieved in rats. Since during isolation of RNA the con-
taminating DNA is treated with DNAse, the amplification
of injected p21 sense plamsid DNA can be ruled out. The
expression of p21WAF1/CIP1 protein using western blot
was also detected in spleens, which was the only tissue
analyzed (results not shown).
We then studied the effect of modulation of p21WAF1/
CIP1 on alloimmunity in a rat heart transplant recipients.
We have extensive experience using the completely MHC
mismatched WF (RTlu) into LEW (RTll) strain combina-
tion and have well defined thresholds of cyclosporine-
based immunosuppression. In this model, animals reject
within 7 to 10 days in the absence of immunosuppression
and as late as 180 days with immunosuppression (CsA 2.5
mg/kg). A total of 12 rat transplants divided into four
groups (A-D) were performed. Recipients in Group A
were given one intramuscular injection of empty vector
plasmid DNA (1 mg); Group B rats were given a daily
dose of CsA (2.5 mg/kg). Rats in Group C rats received
three weekly injections of p21WAF1/CIP1 sense plasmid
DNA (0.5 mg); and Group D rats were given one intra-
muscular injection of p21WAF1/CIP1 sense plasmid DNA
and a daily injection of CsA (2.5 mg/Kg). The allografts
were followed by palpitation, and an arbitrary scale of 1–
4 was used to rate the heartbeat to determine the time of
graft rejection. The rats were sacrificed when a heartbeat of
1–2 was recorded, which was considered as a cutoff for
rejection. Though the number of transplants is low, yet as
shown in Figure 4B, p21WAF1/CIP1 alone (*p < 0.04) or
in combination with CsA (**p < 0.005) significantly pro-
longed the graft survival.
Over expression of p21WAF1/CIP1 inhibits proliferation and  IL-2 mRNA expression in Jurkat T cells Figure 3
Over expression of p21WAF1/CIP1 inhibits prolifera-
tion and IL-2 mRNA expression in Jurkat T cells: A: A 
comparison of the proliferation of Jurkat T cells with and 
without p21 overexpression. B. Il-2 mRNA expression in 
PHA activated normal and p21 over-expressing Jurkat T cells. 
An identical expression of house keeping gene β-actin is also 
shown. C: p21 protein expression in four different clones of 
p21 overexpressing Jurkat T cells, Untreated (lane 1), p21 
overexpressing (lane 2–5) and transfected with empty vector 
DNA (lane 6).
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To confirm that this effect was due to the inhibition of
alloimmune activation, we studied the expression mRNA
of IL-2 in lymphocytes isolated from spleens and heart
allografts. We also examined the expression of IL-10
mRNA in lymphocytes and allografts. The results are
shown in the Figure 4C. The expression of IL-2 mRNA
both in lymphocytes and allografts was higher in animals
injected with empty vector plasmid DNA demonstrating
increased allo-immune activation. IL-2 mRNA expression
decreased significantly in recipients treated with
p21WAF1/CIP1 sense plasmid DNA alone or together
with CsA. The expression of IL-2, correlated with rejection,
which indicated an increased immune activity due to allo-
immune response resulting in the rejection as compared
to p21WAF1/CIP1 or p21WAF1/CIP1 /CsA treated recipi-
ents. We did not observe any significant changes in the
expression of IL-10 mRNA in allografts, which decreased
in animals treated with p21WAF1/CIP1 sense plasmid
DNA alone or with CsA, however it did not reach a level
of significance (Figure 4C).
Discussion
The experiments performed in this study were designed to
understand the role of cyclins on mitogen and allo-stimu-
lation of immune cells and also, if the inhibition of cyc-
lins will correlate with pro-inflammatory cytokines. We
also studied if p21WAF1/CIP1 modulation in recipients
of cardiac transplantation modulates allo- and mitogenic
stimuli and allograft survival. The results demonstrate that
during lymphocyte activation, mRNA expression of cyc-
lins and pro-inflammatory cytokines is significantly
increased and CsA inhibited lymphocyte activation,
mRNA expression of cyclins, pro inflammatory cytokines
but induced p21 mRNA and protein expression.
Studies [9-12] have demonstrated that the expression of
cyclin D3, cdk6, and cyclin E is activated in IL-2-stimu-
lated T lymphocytes. However, the novel finding of this
present study is that mRNA expression of cyclins in acti-
vated lymphocytes correlates with that of pro-inflamma-
tory cytokines, and the expression of both the cyclins and
pro-inflammatory cytokines is inhibited by
immunosuppressive agent CsA. These are novel findings
not demonstrated previously. Our results emphasize that
the cell cycle progression and inflammation are concerted
events thus regulation of cell cycle control could result in
decreased inflammation.
Our in vitro findings on the increased expression of cyclins
mRNA in activated lymphocytes were reproduced in our
in vivo studies. The mRNA expressions of cyclin D3, G and
E in lymphocytes (possible predominantly T cells, CsA
inhibits proliferation of T lymphocytes) isolated from
spleens from untreated recipients of rat cardiac transplant
were significantly higher than those treated with
cyclosporine. The increased expression of cyclins may rep-
resent an uncontrolled allo-immune activation in these
rats. Since CsA treatment resulted in the inhibition of allo-
immune activation and increased graft survival accompa-
nied by a significant inhibition of mRNA expression of
cyclins in CsA treated. This possibly was due to the CsA
mediated inhibition of alloimmune activation. These
results indicate the presence of an active cell cycle progres-
sion during allo-immune activation. Therefore, the con-
trol of cell cycle progression should prevent inflammation
p21WAF1/CIP1 over-expression prolongs allograft survival Figure 4
p21WAF1/CIP1 over-expression prolongs allograft 
survival: A: p21 Injection of p21 sense plasmid DNA 
injected mice (set 2not empty vector plasmid DNA induces 
p21 mRNA expression in heart (h), liver (l), kidney (k) and 
spleen (s). B: Kaplan-Meyer survival graph for rat cardiac 
transplant recipients. Significant difference in the survival of 
allografts in p21WAF1/CIP1 transfected recipients compared 
to controls (* = p < 0.04) and p21WAF1/CIP1 together with 
CsA (* * = p < 0.005) can be seen. C: Effect of p21WAF1/
CIP1 over-expression and CsA treatment on mRNA expres-
sion of IL-2 in lymphocytes and allografts. A significant 
decreased expression of IL-2 mRNA expression in lym-
phocytes and allografts compared to controls is shown (* = p 
< 0.01) and (* * = p < 0.001).
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leading to an improved graft survival. These results are
supported by our studies with MLR cultures using lym-
phocytes from rat heart transplant recipients. An increased
proliferation of lymphocytes accompanied increased
expression of cyclins and pro-inflammatory cytokine
mRNA when responders lymphocytes were used from
untreated rats as compared to those from isografts or CsA
treated rat heart transplant recipients. Again, these acti-
vated lymphocytes were possible predominantly T cells, T
lymphocyte proliferation is a key component of allo-
immune activation. Therefore, these results lend credence
to our thinking that the inhibition of allo-immune activa-
tion accompanies decreased expression of cyclins and pro-
inflammatory cytokines.
These results confirm that control of cell cycle progression
plays a significant role in T cell proliferation/activation.
Role of p21 in other aspects of lymphocyte proliferation
has been studied. Studies of Balomenos et.al, [13] San-
tiago-Raber et al [14] and Brian et al [15] demonstrated
that T lymphocytes from p21WAF1/CIP1-/- mice prolifer-
ated significantly more than from wild type mice upon
stimulation. These results support our studies that
p21WAF1/CIP1 modulation alters cell cycle progression
and the immune system. Jackson et al [16] showed that
increased levels of p21WAF1/CIP1 at the end of G (1)
could prevent cdk-mediated entry into S phase, leading to
proliferative unresponsiveness also found in our experi-
ments with p21WAF1/CIP1 over-expressing Jurkat T cells.
The results from this study are of significance because p21
is one of the most potent regulators of the cell cycle and is
known to inhibit cell proliferation in two different ways.
p21 binds to Cdk2 and inhibits PCNA (proliferating cell
nuclear antigen), which is an auxiliary protein in DNA
polymerase needed for DNA synthesis and nucleotide
excise-n- repair [17]. PCNA has 6 binding sites for p21
[18]. Studies also [19] demonstrated that the PCNA bind-
ing and inhibitory activities reside in the C-terminal
domain of p21, compared to the location of the CDK
inhibitory activity in the conserved N-terminal domain.
The authors also concluded that the CDK and PCNA
inhibitory domains prevented DNA replication suggested
a dual function of p21 as a cell-cycle inhibitor in vivo. We
conducted these studies exclusively with cyclin kinase
inhibitor p21WAF1/CIP1, though p53 and cyclin kinase
inhibitors (p27, p16) have been shown to inhibit cell
cycle yet p16 and p21WAF1/CIP1 inhibit cell cycle pro-
gression through distinct mechanisms [20]. The specific
target for p16 is the Cdk/4cyclin D complex and in a
tumor model, p21WAF1/CIP1 and p16 did not show
additive or synergistic effects [21]. Furthermore in con-
trast to p21WAF1/CIP1, the expression of p27 is not
under transcriptional control and its mRNA expression
remains unchanged during cell cycle [22]. Also, high lev-
els of p27 but not p21WAF1/CIP1 are observed in most
quiescent cells and the inhibition of p27 levels precedes
the progression of cell cycle [23]. Though both p21WAF1/
CIP1 and p27 are critical in the response of cells to
mitogens, p21WAF1/CIP1 provides a better balance
between cyclins and cyclin kinase inhibitors [24] stressing
its significance in inhibition of proliferation/immunosup-
pression. It is therefore possible that p21WAF1/CIP1 over-
expression could interrupt the cell cycle progress and also
prevent inflammation. It is well known that during T cell
activation, expression of pro-inflammatory cytokines IFN-
γ, TNF-α and IL-6 is significantly increased. Since T cells
are the key mediators of allo-immune activation, this
increased expression of cytokines in organ transplant
recipient results in graft rejection [25-27]. Our results
demonstrate a parallel increase in the expression of cyc-
lins and pro-inflammatory cytokines. Therefore an inhibi-
tion/regulation of cell cycle progression of immune cells
by over-expression of cyclin kinase inhibitor p21WAF1/
CIP1 would decrease both allo-immune activation and
inflammation in transplant recipients.
We also demonstrate that rats transfected with p21WAF1/
CIP1 plasmid DNA over expressed p21WAF1/CIP1 mRNA
in different tissues. The recipients of cardiac allograft ani-
mals who received intra-muscular injection of p21WAF1/
CIP1 sense plasmid DNA had significantly increased graft
survival compared to the recipients transfected with
empty plasmid DNA. These very preliminary studies sug-
gest that p21 overexpression can prolong graft survival to
a degree comparable to prolongation by CsA. Further
studies will surely be required to confirm and quantify the
effect of p21 on graft survival. We also present unique
results that the expression of IL-2 mRNA was significantly
decreased in both lymphocytes and allografts isolated
from p21WAF1/CIP1 over-expressing recipients of rat
heart transplants.
Our method of using plasmid DNA to obtain in vitro and
in vivo transfection of p21WAF1/CIP1 is based on the data
supporting the efficacy of intra-muscular injection of plas-
mid DNA for a number of genes [28]. A number of studies
[29-32] have demonstrated that non-viral plasmid DNA
provides a simple, safe, and viable alternative for gene
therapy involving muscle tissue resulting in high level of
expression. More significantly plasmids do not induce
neutralizing immunity, which permits repeated adminis-
tration. Rauh et al [33] tested the hypothesis that intra-
muscular injection of naked DNA could result in the
distribution remote from the site of needle placement,
facilitating intramuscular gene transfer. Using transcuta-
neous ultrasound imaging the authors demonstrated that
a solution of plasmid DNA administered by direct intra-
muscular injection into the skeletal muscles of the limb is
distributed well beyond the site of needle entry andBMC Immunology 2005, 6:22 http://www.biomedcentral.com/1471-2172/6/22
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persisted for 8–10 weeks. Therefore, based on these and
our own studies [7], we believe that the p21WAF1/CIP1
over-expression can be obtained through intramuscular
injections of plasmid DNA, which could result in the
decreased responsiveness of T lymphocytes to allo-and
mitogenic stimuli.
In summary, the results from this study uniquely demon-
strate that during lymphocyte activation, expression of
cyclins is increased and the inhibition of lymphocyte acti-
vation by cyclosporine inhibits the expression of cyclins
and increases the expression of cyclin kinase inhibitor
p21WAF1/CIP1. The expression of cyclins correlates with
that of pro-inflammatory cytokines like TNF-α and IFN-γ
in vitro in activated lymphocytes and in vivo in lym-
phocytes from animals with rejecting rat heart transplants.
These studies demonstrate that cyclins and pro-inflamma-
tory cytokines are key mediators of allo-immune activa-
tion and the alteration of p21WAF1/CIP1 expression can
modulate lymphocyte proliferation and allo-immune
activation. These studies uniquely provide evidence on
the role of cell cycle control molecules on allo-immune
activation and will allow the development of alternate
strategies to obtain improved graft survival in organ trans-
plantation. Moreover based on our previously published
studies, the results presented in this study, and our
recently published study [34] we believe that p21WAF1/
CIP1 might provide better immunosuppression with least
side effects observed with the currently clinically used
immunosuppressive drugs for the organ transplant
recipients.
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